[{"address1": "445 Marine View Avenue", "address2": "Suite 320", "city": "Del Mar", "state": "CA", "zip": "92014", "country": "United States", "phone": "(858) 925-7000", "website": "https://www.lenz-tx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Evert B. Schimmelpennink", "age": 51, "title": "President, CEO, Secretary & Director", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 886536, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Shawn  Olsson", "age": 40, "title": "Chief Commercial Officer", "yearBorn": 1983, "fiscalYear": 2023, "totalPay": 532133, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Marc G. Odrich M.D.", "age": 64, "title": "Chief Medical Officer", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 576950, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James W. McCollum", "age": 68, "title": "Co-Founder & Director", "yearBorn": 1955, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel R. Chevallard CPA", "age": 44, "title": "Chief Financial Officer", "yearBorn": 1979, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Domenick  Porfidia", "title": "Vice President of Sales", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Murphy", "title": "Vice President of Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Breianna  Bowen", "title": "Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Marvin J. Garrett", "age": 72, "title": "Senior Vice President of Regulatory & Quality", "yearBorn": 1951, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 5, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 26.32, "open": 26.2, "dayLow": 25.89, "dayHigh": 28.0, "regularMarketPreviousClose": 26.32, "regularMarketOpen": 26.2, "regularMarketDayLow": 25.89, "regularMarketDayHigh": 28.0, "forwardPE": -10.602272, "volume": 103796, "regularMarketVolume": 103796, "averageVolume": 146387, "averageVolume10days": 121870, "averageDailyVolume10Day": 121870, "marketCap": 769632640, "fiftyTwoWeekLow": 2.01, "fiftyTwoWeekHigh": 28.0, "fiftyDayAverage": 23.2208, "twoHundredDayAverage": 15.62675, "currency": "USD", "enterpriseValue": 575220672, "floatShares": 12512357, "sharesOutstanding": 27496700, "sharesShort": 1946444, "sharesShortPriorMonth": 1983791, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.0708, "heldPercentInsiders": 0.02794, "heldPercentInstitutions": 0.86240995, "shortRatio": 13.62, "bookValue": 7.464, "priceToBook": 3.7499998, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -69474000, "trailingEps": -2.74, "forwardEps": -2.64, "pegRatio": -0.32, "enterpriseToEbitda": -7.643, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "LENZ", "underlyingSymbol": "LENZ", "shortName": "LENZ Therapeutics, Inc.", "longName": "LENZ Therapeutics, Inc.", "firstTradeDateEpochUtc": 1624627800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d24b15aa-881d-34ad-927c-2442ad2e5710", "gmtOffSetMilliseconds": -14400000, "currentPrice": 27.99, "targetHighPrice": 38.0, "targetLowPrice": 31.0, "targetMeanPrice": 34.33, "targetMedianPrice": 34.0, "recommendationMean": 1.4, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 6, "totalCash": 196112000, "totalCashPerShare": 7.132, "ebitda": -75263000, "totalDebt": 1701000, "quickRatio": 22.849, "currentRatio": 23.226, "debtToEquity": 0.882, "operatingCashflow": -73790000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-21"}]